Compare UTF & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | ADPT |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2004 | 2019 |
| Metric | UTF | ADPT |
|---|---|---|
| Price | $26.90 | $16.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $17.78 |
| AVG Volume (30 Days) | 370.3K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $22.05 | $6.26 |
| 52 Week High | $27.33 | $20.76 |
| Indicator | UTF | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 50.92 |
| Support Level | $26.65 | $14.87 |
| Resistance Level | $27.18 | $17.72 |
| Average True Range (ATR) | 0.30 | 0.76 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 53.72 | 79.50 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).